Inhibikase Therapeutics
IKT
24 hedge funds and large institutions have $6.33M invested in Inhibikase Therapeutics in 2022 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 6 reducing their positions, and 4 closing their positions.
0.26% less ownership
Funds ownership: 3.09% → 2.83% (-0.26%)
4% less funds holding
Funds holding: 25 → 24 (-1)
8% less capital invested
Capital invested by funds: $6.85M → $6.33M (-$521K)
17% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 6
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HLA
Hamilton Lane Advisors
Conshohocken,
Pennsylvania
|
+$222K |
| 2 |
RAM
Redmond Asset Management
Henrico,
Virginia
|
+$165K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$68.9K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$17.1K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$6.82K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$437K |
| 2 |
M
Murchinson
Toronto,
Ontario, Canada
|
-$327K |
| 3 |
LCM
Lynwood Capital Management
Toronto,
Ontario, Canada
|
-$181K |
| 4 |
RPCONE
Retirement Planning Company of New England
Warwick,
Rhode Island
|
-$41.5K |
| 5 |
Renaissance Technologies
New York
|
-$17.1K |
IKT Hedge Fund Activity: Q1 2022 in Review
24 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Inhibikase Therapeutics (IKT) for Q1 2022, worth a combined $6.33M — down 7.6% from $6.85M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of IKT and 3 opened new positions — a net loss of 1 holder — while 6 trimmed existing stakes and 5 added.
The largest buyer was Hamilton Lane Advisors, opening a new position worth an estimated $222K. The largest seller was Sabby Management, cutting an estimated $437K.
- 24 institutional investors held Inhibikase Therapeutics (IKT) as of Q1 2022, down from 25 in Q4 2021.
- Funds reported $6.33M of Inhibikase Therapeutics stock for Q1 2022, down 7.6% quarter-over-quarter.
- 3 funds opened new Inhibikase Therapeutics positions in Q1 2022 and 4 closed out, a net change of -1 holder.
- The largest Inhibikase Therapeutics buyer in Q1 2022 was Hamilton Lane Advisors, an estimated $222K added.
- The largest Inhibikase Therapeutics seller in Q1 2022 was Sabby Management, an estimated $437K sold.
Based on aggregated 13F filings for Q1 2022.